CRISM Therapeutics Corporation (AIM:CRTX)

Market Cap	7.03M
Revenue (ttm)	25.00K
Net Income (ttm)	-607.00K
Shares Out	32.68M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,035
Average Volume	41,923
Open	21.40
Previous Close	21.50
Day's Range	19.00 - 23.00
52-Week Range	5.00 - 30.90
Beta	0.27
RSI	52.60
Earnings Date	Jun 19, 2025

About CRISM Therapeutics

CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs. Its lead product is ChemoSeed, an implantable biodegradable drug delivery technology for the delivery of chemotherapy directly into cancer tissues. The company also offers formulation and consultancy services. The company was formerly known as Amur Minerals Corporation and changed its name to CRISM Therapeutics Corporation in May 2024. CRISM Therapeutics Corporati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 4
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CRTX

Financial Performance

In 2024, CRISM Therapeutics's revenue was 25,000, a decrease of -44.44% compared to the previous year's 45,000. Losses were -607,000, 209.7% more than in 2023.